Semaglutide's Indian patent expired on 20 March 2026; within weeks, 13 companies had launched 26 branded generics, Novo Nordisk cut its own list prices by up to 48% in response, and the government opened a parallel crackdown on unauthorised sales of the same drugs it had just let a dozen companies copy. All three things are true at once, and none of them cancel each other out.
Healthcare · Chemicals · Trade & Tariffs
India's Semaglutide Patent Cliff: 26 Brands in Weeks, a Price War, and a Government Crackdown
Revised
· v1.0.0 · what changed
Novo Nordisk's composition patent on semaglutide — the molecule behind Ozempic and Wegovy — expired in India on 20 March 2026. By the following Monday, more than a dozen domestic manufacturers had legal clearance to sell their own versions; within weeks, 13 companies had launched 26 distinct branded generics between them, with more than 50 brands expected eventually. It is the cleanest patent-cliff event India's pharma industry has run in years, and it is playing out on three fronts simultaneously: a pricing collapse, a market-share fight between the original innovators, and a regulatory crackdown on the same drug category the government just let a dozen companies copy.
1. The cliff: price and launch pace
CDSCO had cleared the regulatory path well before the patent actually lapsed — formulations for chronic weight management and type-2 diabetes were approved from September to December 2025, with Zydus Lifesciences, Sun Pharma and Alkem Laboratories among those cleared by January 2026. That meant the launch, when it came, was immediate rather than staggered: Sun Pharma, Dr. Reddy's, Alkem, Zydus, Glenmark and Natco Pharma were all in market within days of 21 March. Novo's own Indian pricing had run ₹10,000–22,000 a month depending on brand and dose; the generics that followed launched from as low as ₹1,300 up to around ₹4,200 (Dr. Reddy's diabetes-focused version), a 50%-plus discount at the low end and deeper still at the bottom of the range.
2. The market-share fight this actually disrupted
The more interesting number sits one layer down: India's GLP-1 category was not semaglutide-versus-nothing before this, it was a two-molecule fight between Novo Nordisk's semaglutide and Eli Lilly's tirzepatide (sold as Mounjaro/Zepbound), and Lilly had been winning it. In the single month after patent expiry, that shifted measurably: Eli Lilly's overall India GLP-1 share fell from 61% to 56%, tirzepatide's own share of the category fell from 71% to 64%, and semaglutide's share rose from 25% to 33% — all in March 2026 alone. Novo Nordisk's own branded share held steady at 25% through the same period, but only because it cut its own list prices sharply to compete with its newly cheap generic cousins — reportedly 38% off Ozempic and 48% off Wegovy. The generics didn't just take share from Novo's own branded product; they reshaped the competitive balance between two entirely different companies' drugs.
3. The market this is chasing
The addressable market is large on its own terms before any of this competitive dynamic is added: India had roughly 89.8 million adults living with diabetes as of 2024 (a 10.5% adult prevalence), and weight-loss drug sales specifically have grown roughly tenfold in five years to about $153 million as of 2026, with projections putting that past half a billion dollars by 2030. High prices were the limiting factor before generics arrived — brand pricing at ₹15,000–22,000 a month kept the category a premium product in a market where that is several times an average monthly wage. The price collapse this piece has already quantified is the mechanism that turns a addressable-but-unaffordable market into an actually-served one, which is exactly why the share numbers moved as fast as they did.
4. The government's other hand: a crackdown on the same category
Running in parallel with the launch wave, not after it, India's drug regulator tightened enforcement specifically on GLP-1 drugs. On 10 March 2026 — ten days before the patent even expired — CDSCO issued an advisory to GLP-1 manufacturers explicitly prohibiting surrogate advertisements and indirect promotion, and reinforcing that these remain prescription-only medicines that should not be marketed for off-label weight-loss use. By 24 March, the government had inspected 49 entities — online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics — and flagged irregularities in unauthorised sales and non-compliant promotion at several of them, with notices issued and further enforcement (licence cancellation, penalties, prosecution) threatened for continued non-compliance. The government's own framing, via the state broadcaster, was explicit about the risk: these drugs, used without medical supervision, "may lead to serious adverse effects and related health risks." A cheaper drug reaching more people and a drug regulator worried about how it reaches them are not contradictory positions — they are the predictable two halves of the same fast-moving launch.
5. The export angle still ahead
Everything above is the domestic story. The same semaglutide composition patent is scheduled to lapse in several other large markets later in 2026 and into 2027 — including China, Brazil, Turkey and South Africa — and Indian manufacturers with domestic launch experience already behind them are positioned to move fastest into those markets too. This blog's earlier piece on Dr. Reddy's own semaglutide programme already covers one concrete piece of that export story: its API supply, meant to serve India, Canada and other partner markets through its OneSource CDMO partnership, was itself delayed for months by a manufacturing-scale-up impurity — a reminder that the domestic launch speed documented here does not automatically carry over to export markets without the same process reliability at larger volumes.
Sources: CDSCO approval timeline and formulation-launch reporting (Business Standard, BusinessToday); newsonair.gov.in (All India Radio/Prasar Bharati, the state broadcaster) on the government's 10 and 24 March 2026 regulatory actions and the 49-entity inspection figure, corroborated by Business Standard and Medical Dialogues coverage of the same CDSCO advisory and enforcement sweep; CNBC, Bloomberg, Seeking Alpha and eMarketer reporting on the Eli Lilly/Novo Nordisk market-share shift and Novo's price cuts; malaymail.com (Reuters wire) on the misuse-warning framing, pricing range and market-size figures ($153mn 2026, $500mn+ by 2030 projection). This blog's own "Dr. Reddy's Cut Its Semaglutide Guidance in Half After an API Impurity It Caught Itself," cross-linked rather than repeated in full. Market-share and pricing figures are as reported in company disclosures and trade/financial press, not independently re-derived from raw sales data.
Related on this blog
See also: Dr. Reddy's Cut Its Semaglutide Guidance in Half After an API Impurity It Caught Itself · India Cannot Sell “China-Free” Medicine While Importing 43% of What's In It.
- v1.0.0 — 16 September 2026 — first published.
About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.
